Albany, New York, April 24, 2015 : Market Research Reports Search Engine (MRRSE) has announced the addition of the ‘ Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation’ report by GBI Research to its rapidly growing market research report database. The report discusses more than 300 therapies for Parkinson’s disease in the pipeline, including over 90 first-in-class therapies. The report segments the pipeline products by phase, molecule type, and therapeutic target. The report describes the key fact that the mechanism of action of most current and pipeline therapies for Parkinson’s disease is different: most current therapies focus on neuromodulatory receptors, whereas a majority of pipeline products act in a neuroprotective fashion, targeting and eliminating dysfunctional disease processes.

1. Fragmented Market for Parkinson’s Disease Therapeutics
Offers Profitable Prospects for Consolidation
Published By:
GBI Research Market
Research
Contact US:
Tel: +1-518-618-1030
Email: sales@mrrse.com
Toll Free : 866-997-4948 (US-
CANADA)

2. Report Description
Albany, New York, April 24, 2015 : Market Research Reports Search Engine (MRRSE) has announced the
addition of the ‘ Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class
Innovation’ report by GBI Research to its rapidly growing market research report database. The report
discusses more than 300 therapies for Parkinson’s disease in the pipeline, including over 90 first-in-class
therapies. The report segments the pipeline products by phase, molecule type, and therapeutic target.
The report describes the key fact that the mechanism of action of most current and pipeline therapies for
Parkinson’s disease is different: most current therapies focus on neuromodulatory receptors, whereas a
majority of pipeline products act in a neuroprotective fashion, targeting and eliminating dysfunctional
disease processes.
Complete Report with TOC @ http://www.mrrse.com/parkinson-disease-therapeutics-market-report

3. Scope
Parkinson's disease (PD) is a progressive neurological health condition that features a clichéd interplay
between a number of pathological processes and features neurodegeneration as one of its key effects. In
the U.S. alone, nearly 50,000 - 60,000 new cases of PD are diagnosed every year. Other than these, there
are already nearly one million patients of PD in the US and nearly four to six million PD patients in the
entire world. It is ranked as the 14th leading cause of death in the US. The exact cause behind PD is not
clear. Still, scientists are working towards a cure for the condition and many therapeutic methods are in
their developmental phases.

4. Table of Contents
Table of Content
1 Table of Contents 2
2 Executive Summary 5
3 The Case for Innovation 6
4 Clinical and Commercial Landscape 10
5 Assessment of Pipeline Product Innovation 37
6 Signaling Network, Parkinson’s Disease Genetics and Innovation Alignment 46
7 First-in-Class Target and Pipeline Program Evaluation 54
8 Deals and Strategic Consolidations 93
9 Appendix 106
Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/131

5. Corporate Office
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@mrrse.com
Toll Free : 866-997-4948 (US-CANADA)
Contact Us
Read More @ http://www.mrrse.com/